에서 실시간으로 운영 중이에요! 자세히 알아보기

Deciphera Pharmaceuticals, Inc. Common Stock

DCPH

시가총액 US$22.1억

상장 폐지됨

DCPH 종목은 2024년 6월 10일에 상장 폐지됐어요.

순위로 돌아가기

소개: Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.

직원 수: 355

헬스케어 제약 - 종합

뉴스

긍정적

중립

부정적

투자 심리 3개월

긍정적 0%

중립 0%

부정적 0%

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that results from the Company's MOTION pivotal Phase 3 study of vimseltinib in patients with TGCT are being highlighted in an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois,.

Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet

Zacks Investment Research

Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why

Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.

Zacks Investment Research

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

While the top- and bottom-line numbers for Deciphera Pharmaceuticals (DCPH) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.60 per share a year ago.

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Deciphera Pharmaceuticals, Inc. (NasdaqGS: DCPH) to ONO Pharmaceutical Co., Ltd. Under the terms of the proposed transaction, shareholders of Deciphera will receive $25.60 in cash for each share of Deciphera that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.

DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

OSAKA, Japan , April 30, 2024 /PRNewswire/ -- ONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH, Chief Executive Officer: Steven L.

ONO Enters into a Definitive Agreement to Acquire Deciphera Pharmaceuticals

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion

Japan's Ono Pharmaceutical Co said on Tuesday its $2.4 billion takeover of Deciphera Pharmaceuticals is a "first step" in expanding in U.S. and European markets.

INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH

NEW YORK , April 29, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and is investigating Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) , relating to its proposed merger with ONO Pharmaceutical Co., Ltd.

INVESTIGATION: The M&A Class Action Firm Announces An Investigation of Deciphera Pharmaceuticals, Inc. - DCPH

ONO to buy Deciphera Pharmaceuticals at a huge premium

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) is up a whopping 75% today after ONO Pharmaceutical (TYO: 4528) announced plans of buying it for $2.4 billion. Deciphera Pharmaceuticals stock valued at $25.60 The cash offer values each share of Deciphera Pharmaceuticals at $25.60.

Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?

Deciphera Pharmaceuticals (NASDAQ: DCPH ) stock is rising higher on Monday after signing a $2.4 billion acquisition agreement with ONO Pharmaceutical. This deal has ONO Pharmaceutical acquiring Deciphera Pharmaceuticals for $25.60 per share in cash.

뉴스 순위 보기

Lightweight Charts™를 사용해 가격 차트를 구현했어요.